{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,9]],"date-time":"2026-11-09T10:41:48Z","timestamp":1794220908466,"version":"4.8.0"},"reference-count":57,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,6,3]],"date-time":"2025-06-03T00:00:00Z","timestamp":1748908800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,6,3]],"date-time":"2025-06-03T00:00:00Z","timestamp":1748908800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"NIH","award":["R01 AG027161"],"award-info":[{"award-number":["R01 AG027161"]}]},{"name":"NIH","award":["R01 AG027161"],"award-info":[{"award-number":["R01 AG027161"]}]},{"name":"NIH","award":["R01 AG027161"],"award-info":[{"award-number":["R01 AG027161"]}]},{"name":"NIH","award":["R01 AG031790"],"award-info":[{"award-number":["R01 AG031790"]}]},{"name":"NIH","award":["R01 AG027161"],"award-info":[{"award-number":["R01 AG027161"]}]},{"name":"NIH","award":["R01 AG062167"],"award-info":[{"award-number":["R01 AG062167"]}]},{"name":"NIH","award":["R01 AG037639"],"award-info":[{"award-number":["R01 AG037639"]}]},{"name":"NIH","award":["P30 AG06715"],"award-info":[{"award-number":["P30 AG06715"]}]},{"name":"NIH","award":["R01 AG027161"],"award-info":[{"award-number":["R01 AG027161"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"DOI":"10.1038\/s41598-025-04319-3","type":"journal-article","created":{"date-parts":[[2025,6,3]],"date-time":"2025-06-03T08:29:23Z","timestamp":1748939363000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":14,"title":["Synaptic markers are associated with cognitive decline after accounting for amyloid burden among an at-risk Alzheimer\u2019s disease cohort"],"prefix":"10.1038","volume":"15","author":[{"given":"Elizabeth M.","family":"Planalp","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rebecca E.","family":"Langhough","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erin M.","family":"Jonaitis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carol A.","family":"Van Hulle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rachael E.","family":"Wilson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gwendlyn","family":"Kollmorgen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Clara","family":"Quijano-Rubio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ozioma C.","family":"Okonkwo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Barbara B.","family":"Bendlin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sanjay","family":"Asthana","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kaj","family":"Blennow","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Henrik","family":"Zetterberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sterling C.","family":"Johnson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,6,3]]},"reference":[{"key":"4319_CR1","doi-asserted-by":"publisher","first-page":"535","DOI":"10.1016\/j.jalz.2018.02.018","volume":"14","author":"CR Jack","year":"2018","unstructured":"Jack, C. R. et al. NIA-AA research framework: toward a biological definition of alzheimer\u2019s disease. Alzheimers Dement. 14, 535\u2013562 (2018).","journal-title":"Alzheimers Dement."},{"key":"4319_CR2","doi-asserted-by":"publisher","first-page":"539","DOI":"10.1212\/WNL.0000000000002923","volume":"87","author":"CR Jack Jr","year":"2016","unstructured":"Jack, C. R. Jr. et al. A\/T\/N: an unbiased descriptive classification scheme for alzheimer disease biomarkers. Neurology 87, 539\u2013547 (2016).","journal-title":"Neurology"},{"key":"4319_CR3","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1016\/S1474-4422(12)70291-0","volume":"12","author":"CR Jack Jr","year":"2013","unstructured":"Jack, C. R. Jr. et al. Tracking pathophysiological processes in alzheimer\u2019s disease: an updated hypothetical model of dynamic biomarkers. Lancet Neurol. Feb. 12, 207\u2013216 (2013).","journal-title":"Lancet Neurol. Feb"},{"key":"4319_CR4","doi-asserted-by":"publisher","first-page":"5143","DOI":"10.1002\/alz.13859","volume":"20","author":"CR Jack","year":"2024","unstructured":"Jack, C. R. et al. Revised criteria for diagnosis and staging of alzheimer\u2019s disease: alzheimer\u2019s association workgroup. Alzheimers Dement. 20, 5143\u20135169 (2024).","journal-title":"Alzheimers Dement."},{"key":"4319_CR5","doi-asserted-by":"crossref","unstructured":"Allison, S. L. et al. Comparison of different MRI-based morphometric estimates for defining neurodegeneration across the alzheimer\u2019s disease continuum. Neuroimage Clin 23, (2019).","DOI":"10.1016\/j.nicl.2019.101895"},{"key":"4319_CR6","doi-asserted-by":"publisher","first-page":"e043987","DOI":"10.1002\/alz.043987","volume":"16","author":"RL Gallagher","year":"2020","unstructured":"Gallagher, R. L. et al. CSF NFL levels and neuroimaging-derived neurite density index improve prediction of MCI and dementia clinical diagnosis within the alzheimer\u2019s pathologic framework: biomarkers (non\u2010neuroimaging) \/ Multi\u2010modal comparisons. Alzheimers Dement. 16, e043987 (2020).","journal-title":"Alzheimers Dement."},{"key":"4319_CR7","doi-asserted-by":"crossref","unstructured":"Jin, M., Cao, L. & Dai, Y. Role of neurofilament light chain as a potential biomarker for alzheimer\u2019s disease: A correlative Meta-Analysis. Front Aging Neurosci 11, (2019).","DOI":"10.3389\/fnagi.2019.00254"},{"key":"4319_CR8","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1016\/j.trci.2019.02.004","volume":"5","author":"AP Merluzzi","year":"2019","unstructured":"Merluzzi, A. P. et al. Differential effects of neurodegeneration biomarkers on subclinical cognitive decline. Alzheimers Dement. Transl Res. Clin. Interv. 5, 129\u2013138 (2019).","journal-title":"Alzheimers Dement. Transl Res. Clin. Interv"},{"key":"4319_CR9","doi-asserted-by":"publisher","first-page":"1945","DOI":"10.1212\/WNL.0000000000001015","volume":"83","author":"T Skillb\u00e4ck","year":"2014","unstructured":"Skillb\u00e4ck, T. et al. CSF neurofilament light differs in neurodegenerative diseases and predicts severity and survival. Neurology 83, 1945\u20131953 (2014).","journal-title":"Neurology"},{"key":"4319_CR10","doi-asserted-by":"crossref","unstructured":"Nilsson, J. et al. Cerebrospinal fluid biomarker panel for synaptic dysfunction in a broad spectrum of neurodegenerative diseases. Brain awae032 (2024).","DOI":"10.1093\/brain\/awae032"},{"key":"4319_CR11","doi-asserted-by":"publisher","first-page":"1782","DOI":"10.1212\/WNL.0000000000004569","volume":"89","author":"KB Casaletto","year":"2017","unstructured":"Casaletto, K. B. et al. Neurogranin, a synaptic protein, is associated with memory independent of alzheimer biomarkers. Neurology 89, 1782\u20131788 (2017).","journal-title":"Neurology"},{"key":"4319_CR12","doi-asserted-by":"publisher","first-page":"1275","DOI":"10.1001\/jamaneurol.2015.1867","volume":"72","author":"MI Kester","year":"2015","unstructured":"Kester, M. I. et al. Neurogranin as a cerebrospinal fluid biomarker for synaptic loss in symptomatic alzheimer disease. JAMA Neurol. 72, 1275\u20131280 (2015).","journal-title":"JAMA Neurol."},{"key":"4319_CR13","doi-asserted-by":"publisher","first-page":"7","DOI":"10.3389\/fnsyn.2016.00007","volume":"8","author":"F Antonucci","year":"2016","unstructured":"Antonucci, F. et al. SNAP-25, a known presynaptic protein with emerging postsynaptic functions. Front. Synaptic Neurosci. 8, 7 (2016).","journal-title":"Front. Synaptic Neurosci."},{"key":"4319_CR14","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1007\/s00702-021-02411-2","volume":"129","author":"G\u00f3mez De San Jos\u00e9","year":"2022","unstructured":"G\u00f3mez De San Jos\u00e9. Neuronal pentraxins as biomarkers of synaptic activity: from physiological functions to pathological changes in neurodegeneration. J. Neural Transm. 129, 207\u2013230 (2022).","journal-title":"J. Neural Transm"},{"key":"4319_CR15","doi-asserted-by":"publisher","first-page":"1976","DOI":"10.1002\/alz.12353","volume":"17","author":"O Libiger","year":"2021","unstructured":"Libiger, O. et al. Longitudinal CSF proteomics identifies NPTX2 as a prognostic biomarker of alzheimer\u2019s disease. Alzheimers Dement. 17, 1976\u20131987 (2021).","journal-title":"Alzheimers Dement."},{"key":"4319_CR16","unstructured":"Xiao, M. F. et al. NPTX2 and cognitive dysfunction in Alzheimer\u2019s Disease. elife 6, e23798 (2017)."},{"key":"4319_CR17","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1186\/s13024-024-00705-z","volume":"19","author":"S Mravinacov\u00e1","year":"2024","unstructured":"Mravinacov\u00e1, S. et al. CSF protein ratios with enhanced potential to reflect alzheimer\u2019s disease pathology and neurodegeneration. Mol. Neurodegener. 19, 15 (2024).","journal-title":"Mol. Neurodegener"},{"key":"4319_CR18","doi-asserted-by":"crossref","unstructured":"Jonaitis, E. M. et al. Longitudinal normative standards for cognitive tests and composites using harmonized data from two Wisconsin AD-risk-enriched cohorts. Alzheimers Dement. J. Alzheimers Assoc (2024).","DOI":"10.1002\/alz.13774"},{"key":"4319_CR19","doi-asserted-by":"publisher","first-page":"130","DOI":"10.1016\/j.dadm.2017.11.007","volume":"10","author":"SC Johnson","year":"2018","unstructured":"Johnson, S. C. et al. The Wisconsin registry for alzheimer\u2019s prevention: A review of findings and current directions. Alzheimers Dement. Amst. 10, 130\u2013142 (2018).","journal-title":"Alzheimers Dement. Amst"},{"key":"4319_CR20","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1097\/WAD.0b013e318142774e","volume":"21","author":"DL Beekly","year":"2007","unstructured":"Beekly, D. L. et al. The National alzheimer\u2019s coordinating center (NACC) database: the uniform data set. Alzheimer Dis. Assoc. Disord. 21, 249\u2013258 (2007).","journal-title":"Alzheimer Dis. Assoc. Disord"},{"key":"4319_CR21","doi-asserted-by":"publisher","first-page":"961","DOI":"10.1001\/jamaneurol.2014.803","volume":"71","author":"MC Donohue","year":"2014","unstructured":"Donohue, M. C. et al. The preclinical alzheimer cognitive composite: measuring amyloid-related decline. JAMA Neurol. 71, 961\u2013970 (2014).","journal-title":"JAMA Neurol."},{"key":"4319_CR22","first-page":"74","volume":"11","author":"EM Jonaitis","year":"2019","unstructured":"Jonaitis, E. M. et al. Measuring longitudinal cognition: individual tests versus composites. Alzheimers Dement. 11, 74\u201384 (2019).","journal-title":"Alzheimers Dement."},{"key":"4319_CR23","unstructured":"Schmidt, M. Rey Auditory Verbal Learning Test: A Handbook (Western Psychological Services, 1996)."},{"key":"4319_CR24","doi-asserted-by":"publisher","first-page":"134","DOI":"10.1097\/WAD.0000000000000111","volume":"30","author":"SE Monsell","year":"2016","unstructured":"Monsell, S. E. et al. Results from the NACC uniform data set neuropsychological battery crosswalk study. Alzheimer Dis. Assoc. Disord. 30, 134\u2013139 (2016).","journal-title":"Alzheimer Dis. Assoc. Disord"},{"key":"4319_CR25","unstructured":"Wechsler, D. Wechsler memory scale-revised. The psychological corporation. N Y (1987)."},{"key":"4319_CR26","doi-asserted-by":"publisher","first-page":"271","DOI":"10.2466\/pms.1958.8.3.271","volume":"8","author":"RM Reitan","year":"1958","unstructured":"Reitan, R. M. Validity of the trail making test as an indicator of organic brain damage. Percept. Mot Skills. 8, 271\u2013276 (1958).","journal-title":"Percept. Mot Skills"},{"key":"4319_CR27","doi-asserted-by":"publisher","first-page":"688478","DOI":"10.3389\/fnagi.2021.688478","volume":"13","author":"R Langhough Koscik","year":"2021","unstructured":"Langhough Koscik, R. et al. Validity evidence for the research category,cognitively unimpaired\u2013declining, as a risk marker for mild cognitive impairment and alzheimer\u2019s disease. Front. Aging Neurosci. 13, 688478 (2021).","journal-title":"Front. Aging Neurosci."},{"key":"4319_CR28","doi-asserted-by":"publisher","first-page":"270","DOI":"10.1016\/j.jalz.2011.03.008","volume":"7","author":"MS Albert","year":"2011","unstructured":"Albert, M. S. et al. The diagnosis of mild cognitive impairment due to alzheimer\u2019s disease: recommendations from the National Institute on Aging-Alzheimer\u2019s association workgroups on diagnostic guidelines for alzheimer\u2019s disease. Alzheimers Dement. May. 7, 270\u2013279 (2011).","journal-title":"Alzheimers Dement. May"},{"key":"4319_CR29","first-page":"3312024","volume":"7","author":"GM McKhann","year":"2011","unstructured":"McKhann, G. M. et al. The diagnosis of dementia due to alzheimer\u2019s disease: recommendations from the National Institute on Aging-Alzheimer\u2019s association workgroups on diagnostic guidelines for alzheimer\u2019s disease. Alzheimers Dement. May. 7, 3312024 (2011).","journal-title":"Alzheimers Dement. May"},{"key":"4319_CR30","unstructured":"Roche Diagnostics. Elecsys\u00ae Phospho-Tau (181P) CSF. at (2024). https:\/\/diagnostics.roche.com\/us\/en\/products\/params\/elecsys-ptau.html"},{"key":"4319_CR31","unstructured":"Roche Diagnostics. Elecsys\u00ae \u03b2-Amyloid (1\u201342) CSF II. at (2024). https:\/\/diagnostics.roche.com\/us\/en\/products\/params\/elecsys-abeta42.html"},{"key":"4319_CR32","unstructured":"Elecsys\u00ae Phospho-Tau (181P) CSF. at (2021). https:\/\/elabdoc-prod.roche.com\/eLD\/api\/downloads\/7e32f68e-5ab1-eb11-0391-005056a772fd?countryIsoCode=cn"},{"key":"4319_CR33","unstructured":"Elecsys\u00ae \u03b2-Amyloid. (1\u201342) CSF II. Roche Diagn. at https:\/\/diagnostics.roche.com\/us\/en\/products\/params\/elecsys-abeta42.html"},{"key":"4319_CR34","doi-asserted-by":"publisher","first-page":"431","DOI":"10.1002\/alz.12204","volume":"17","author":"C Van Hulle","year":"2021","unstructured":"Van Hulle, C. et al. An examination of a novel multipanel of CSF biomarkers in the alzheimer\u2019s disease clinical and pathological continuum. Alzheimers Dement. J. Alzheimers Assoc. 17, 431\u2013445 (2021).","journal-title":"Alzheimers Dement. J. Alzheimers Assoc."},{"key":"4319_CR35","doi-asserted-by":"publisher","first-page":"6747","DOI":"10.1038\/s41467-023-42596-6","volume":"14","author":"H Cai","year":"2023","unstructured":"Cai, H., Pang, Y., Fu, X., Ren, Z. & Jia, L. Plasma biomarkers predict alzheimer\u2019s disease before clinical onset in Chinese cohorts. Nat. Commun. 14, 6747 (2023).","journal-title":"Nat. Commun."},{"key":"4319_CR36","doi-asserted-by":"publisher","first-page":"1204","DOI":"10.1002\/alz.12751","volume":"19","author":"S Palmqvist","year":"2023","unstructured":"Palmqvist, S. et al. An accurate fully automated panel of plasma biomarkers for alzheimer\u2019s disease. Alzheimers Dement. 19, 1204\u20131215 (2023).","journal-title":"Alzheimers Dement."},{"key":"4319_CR37","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1186\/1471-2105-12-77","volume":"12","author":"X Robin","year":"2011","unstructured":"Robin, X. et al. pROC: an open-source package for R and S\u2009+\u2009to analyze and compare ROC curves. BMC Bioinform. 12, 77 (2011).","journal-title":"BMC Bioinform."},{"key":"4319_CR38","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1002\/1097-0142(1950)3:1<32::AID-CNCR2820030106>3.0.CO;2-3","volume":"3","author":"WJ Youden","year":"1950","unstructured":"Youden, W. J. Index for rating diagnostic tests. Cancer 3, 32\u201335 (1950).","journal-title":"Cancer"},{"key":"4319_CR39","unstructured":"SAS\/STAT\u00ae 15.3 User\u2019s Guide. (2023)."},{"key":"4319_CR40","unstructured":"R Core Team. R: A Language and Environment for Statistical Computing [Internet]. at < (2019). Available from: http:\/\/www.r-project.org"},{"key":"4319_CR41","doi-asserted-by":"publisher","first-page":"323","DOI":"10.3102\/10769986023004323","volume":"23","author":"JD Singer","year":"1998","unstructured":"Singer, J. D. & Using SAS PROC MIXED to fit multilevel models, hierarchical models, and individual growth models. J. Educ. Behav. Stat. 23, 323\u2013355 (1998).","journal-title":"J. Educ. Behav. Stat."},{"key":"4319_CR42","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1007\/s00265-010-1029-6","volume":"65","author":"KP Burnham","year":"2011","unstructured":"Burnham, K. P., Anderson, D. R. & Huyvaert, K. P. AIC model selection and multimodel inference in behavioral ecology: some background, observations, and comparisons. Behav. Ecol. Sociobiol. 65, 23\u201335 (2011).","journal-title":"Behav. Ecol. Sociobiol."},{"key":"4319_CR43","doi-asserted-by":"publisher","unstructured":"Burnham, K. P. & Anderson, D. R. in Model Sel. Inference 75\u2013117Springer New York, (1998). https:\/\/doi.org\/10.1007\/978-1-4757-2917-7_3","DOI":"10.1007\/978-1-4757-2917-7_3"},{"key":"4319_CR44","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1177\/0049124104268644","volume":"33","author":"KP Burnham","year":"2004","unstructured":"Burnham, K. P. & Anderson, D. R. Multimodel inference: Understanding AIC and BIC in model selection. Sociol. Methods Res. 33, 261\u2013304 (2004).","journal-title":"Sociol. Methods Res."},{"key":"4319_CR45","doi-asserted-by":"crossref","unstructured":"Long, J. A. interactions: Comprehensive, User-Friendly Toolkit for Probing Interactions. at (2019). https:\/\/cran.r-project.org\/package=interactions","DOI":"10.32614\/CRAN.package.interactions"},{"key":"4319_CR46","doi-asserted-by":"publisher","first-page":"373","DOI":"10.1207\/s15327906mbr4003_5","volume":"40","author":"DJ Bauer","year":"2005","unstructured":"Bauer, D. J. & Curran, P. J. Probing interactions in fixed and multilevel regression: Inferential and graphical techniques. Multivar. Behav. Res. 40, 373\u2013400 (2005).","journal-title":"Multivar. Behav. Res."},{"key":"4319_CR47","doi-asserted-by":"publisher","first-page":"431","DOI":"10.1002\/(SICI)1522-2683(19990301)20:3<431::AID-ELPS431>3.0.CO;2-2","volume":"20","author":"P Davidsson","year":"1999","unstructured":"Davidsson, P., Puchades, M. & Blennow, K. Identification of synaptic vesicle, pre- and postsynaptic proteins in human cerebrospinal fluid using liquid-phase isoelectric focusing. ELECTROPHORESIS 20, 431\u2013437 (1999).","journal-title":"ELECTROPHORESIS"},{"key":"4319_CR48","doi-asserted-by":"publisher","first-page":"117727192095031","DOI":"10.1177\/1177271920950319","volume":"15","author":"E Camporesi","year":"2020","unstructured":"Camporesi, E. et al. Fluid biomarkers for synaptic dysfunction and loss. Biomark. Insights. 15, 1177271920950319 (2020).","journal-title":"Biomark. Insights"},{"key":"4319_CR49","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1186\/s13195-023-01212-x","volume":"15","author":"S Das","year":"2023","unstructured":"Das, S. et al. Synaptic biomarkers in the cerebrospinal fluid associate differentially with classical neuronal biomarkers in patients with alzheimer\u2019s disease and frontotemporal dementia. Alzheimers Res. Ther. 15, 62 (2023).","journal-title":"Alzheimers Res. Ther."},{"key":"4319_CR50","unstructured":"Wagemann, O. et al. Downstream Biomarker Effects of Gantenerumab or Solanezumab in Dominantly Inherited Alzheimer Disease: The DIAN-TU-001 Randomized Clinical Trial. JAMA Neurol. at (2024). https:\/\/jamanetwork.com\/journals\/jamaneurology\/article-abstract\/2817630"},{"key":"4319_CR51","doi-asserted-by":"publisher","first-page":"e202402793","DOI":"10.26508\/lsa.202402793","volume":"7","author":"F Li","year":"2024","unstructured":"Li, F. et al. Morphological correlates of synaptic protein turnover in the mouse brain. Life Sci. Alliance. 7, e202402793 (2024).","journal-title":"Life Sci. Alliance"},{"key":"4319_CR52","doi-asserted-by":"publisher","first-page":"e63191","DOI":"10.1371\/journal.pone.0063191","volume":"8","author":"LD Cohen","year":"2013","unstructured":"Cohen, L. D. et al. Metabolic turnover of synaptic proteins: kinetics, interdependencies and implications for synaptic maintenance. PLOS ONE. 8, e63191 (2013).","journal-title":"PLOS ONE"},{"key":"4319_CR53","doi-asserted-by":"publisher","first-page":"eadf0141","DOI":"10.1126\/scitranslmed.adf0141","volume":"15","author":"J Zhou","year":"2023","unstructured":"Zhou, J. et al. The neuronal pentraxin Nptx2 regulates complement activity and restrains microglia-mediated synapse loss in neurodegeneration. Sci. Transl Med. 15, eadf0141 (2023).","journal-title":"Sci. Transl Med."},{"key":"4319_CR54","doi-asserted-by":"publisher","first-page":"1943","DOI":"10.1038\/s41386-018-0091-z","volume":"43","author":"S Chang","year":"2018","unstructured":"Chang, S. et al. NPTX2 is a key component in the regulation of anxiety. Neuropsychopharmacology 43, 1943\u20131953 (2018).","journal-title":"Neuropsychopharmacology"},{"key":"4319_CR55","doi-asserted-by":"crossref","unstructured":"Chapman, G., Shanmugalingam, U. & Smith, P. D. The role of neuronal pentraxin 2 (NP2) in regulating glutamatergic signaling and neuropathology. Front Cell. Neurosci 13, (2020).","DOI":"10.3389\/fncel.2019.00575"},{"key":"4319_CR56","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1001\/jamaneurol.2023.5319","volume":"81","author":"NJ Ashton","year":"2024","unstructured":"Ashton, N. J. et al. Diagnostic accuracy of a plasma phosphorylated Tau 217 immunoassay for alzheimer disease pathology. JAMA Neurol. 81, 255\u2013263 (2024).","journal-title":"JAMA Neurol."},{"key":"4319_CR57","unstructured":"Jonaitis, E. M. et al. Plasma pTau-217 in preclinical Alzheimer\u2019s disease."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-04319-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-04319-3","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-04319-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,3]],"date-time":"2025-06-03T08:29:29Z","timestamp":1748939369000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-04319-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6,3]]},"references-count":57,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["4319"],"URL":"https:\/\/doi.org\/10.1038\/s41598-025-04319-3","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,6,3]]},"assertion":[{"value":"1 October 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 May 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 June 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Competing interestsGGK is a full-time employee of Roche Diagnostics GmbH.CQR is a full-time employee of Roche Diagnostics International Ltd.HZ has served at scientific advisory boards and\/or as a consultant for Abbvie, Acumen, Alector, Alzinova, ALZPath, Amylyx, Annexon, Apellis, Artery Therapeutics, AZTherapies, Cognito Therapeutics, CogRx, Denali, Eisai, LabCorp, Merry Life, Nervgen, Novo Nordisk, Optoceutics, Passage Bio, Pinteon Therapeutics, Prothena, Red Abbey Labs, reMYND, Roche, Samumed, Siemens Healthineers, Triplet Therapeutics, and Wave, has given lectures in symposia sponsored by Alzecure, Biogen, Cellectricon, Fujirebio, Lilly, Novo Nordisk, and Roche, and is a co-founder of Brain Biomarker Solutions in Gothenburg AB (BBS), which is a part of the GU Ventures Incubator Program (outside submitted work).SCJ serves on advisory boards for ALZPath and Enigma Biomedical. EMP, RL, EJ, CAVH, REW, OCO, BB, SA, KJ report no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"19399"}}